Post-authorisation Safety Study of NOCDURNA for the Symptomatic Treatment of Nocturia Due to Idiopathic Nocturnal Polyuria: A Multi-country Cohort Study Using Secondary Data
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Adverse reactions
- Acronyms NOCDURNA PASS
- Sponsors Ferring Pharmaceuticals
- 17 Jul 2024 Status changed from recruiting to completed.
- 02 Feb 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2023.
- 28 Jul 2021 Status changed from not yet recruiting to recruiting.